Michael Foote, MD

GI Oncology Now

<p>Michael Foote, MD, Memorial Sloan Kettering Cancer Center, discusses the ALASCCA study presented at ASCO GI 2025, which examined the impact of aspirin on recurrence risk in patients with resected stage 2 and 3 colorectal cancer with PIK3CA mutations. The study found that low-dose aspirin significantly reduced the 3-year cumulative incidence of recurrence, particularly in patients with PIK3CA exon 9 or 20 mutations. Dr. Foote explores the potential metabolic rationale behind aspirin&rsquo;s effect in this subgroup and explains why this data could be impactful to clinical practice.</p>


Emily Menendez

FDA Approves Nivolumab Plus Ipilimumab for dMMR CRC Based on CheckMate-8HW Results

Colorectal Cancer

Leah Lawrence

Ongoing Research Continues to Advance Management of HCC

Liver Cancer

Can Aspirin Prevent Recurrence in Early-Stage Colorectal Cancer? Insights from the ALASCCA Study

Latest News

Low-dose aspirin halved recurrence in resected PIK3CA-mutated colorectal cancer, per data from the ALASCCA trial.

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

GU Oncology Now

Lung Cancers Today

Cancer Nursing Today

DocWire News

MashupMD

Bile Duct

Colorectal

Esophageal

Gastric

GEP-NETs

GIST

Liver

Pancreatic

Conference Coverage

Video Insights

Roundtable